Fiduciary Group LLC Purchases 53,129 Shares of Kenvue Inc. (NYSE:KVUE)

Fiduciary Group LLC grew its stake in Kenvue Inc. (NYSE:KVUE - Free Report) by 82.0% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 117,881 shares of the company's stock after buying an additional 53,129 shares during the quarter. Fiduciary Group LLC's holdings in Kenvue were worth $2,538,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also made changes to their positions in KVUE. Clearstead Advisors LLC acquired a new stake in shares of Kenvue during the 3rd quarter worth about $25,000. Planned Solutions Inc. acquired a new stake in shares of Kenvue during the 4th quarter worth about $27,000. Global Retirement Partners LLC acquired a new position in Kenvue during the third quarter worth approximately $28,000. Venturi Wealth Management LLC acquired a new position in Kenvue during the third quarter worth approximately $28,000. Finally, EverSource Wealth Advisors LLC acquired a new position in Kenvue during the third quarter worth approximately $28,000. Institutional investors and hedge funds own 97.64% of the company's stock.

Kenvue Trading Down 0.8 %

Shares of Kenvue stock traded down $0.16 during trading on Friday, reaching $18.86. The company's stock had a trading volume of 15,454,689 shares, compared to its average volume of 13,458,618. The company has a quick ratio of 0.78, a current ratio of 1.12 and a debt-to-equity ratio of 0.69. Kenvue Inc. has a 12-month low of $17.82 and a 12-month high of $27.80. The business has a 50 day moving average price of $19.84 and a 200-day moving average price of $20.14.

Kenvue (NYSE:KVUE - Get Free Report) last posted its quarterly earnings results on Thursday, February 8th. The company reported $0.31 earnings per share for the quarter, beating analysts' consensus estimates of $0.28 by $0.03. Kenvue had a return on equity of 15.62% and a net margin of 9.87%. The firm had revenue of $3.67 billion for the quarter, compared to the consensus estimate of $3.78 billion. Kenvue's revenue for the quarter was down 2.7% on a year-over-year basis. Equities analysts predict that Kenvue Inc. will post 1.15 EPS for the current fiscal year.

Kenvue Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, May 22nd. Shareholders of record on Wednesday, May 8th will be given a dividend of $0.20 per share. The ex-dividend date is Tuesday, May 7th. This represents a $0.80 dividend on an annualized basis and a yield of 4.24%.

Analyst Ratings Changes

Several research analysts have commented on the company. William Blair assumed coverage on Kenvue in a research report on Wednesday, April 3rd. They set a "market perform" rating on the stock. JPMorgan Chase & Co. cut their price target on Kenvue from $25.00 to $24.00 and set an "overweight" rating on the stock in a research report on Friday, February 9th. The Goldman Sachs Group assumed coverage on Kenvue in a research report on Friday, March 1st. They set a "neutral" rating and a $20.00 price target on the stock. Royal Bank of Canada cut their price target on Kenvue from $25.00 to $24.00 and set an "outperform" rating on the stock in a research report on Friday, February 9th. Finally, Sanford C. Bernstein began coverage on Kenvue in a report on Thursday, April 11th. They issued an "underperform" rating and a $18.00 target price on the stock. One research analyst has rated the stock with a sell rating, eight have given a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $24.85.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.